文献速递妇科

NSGO-OV-UMB1/ENGOT-OV30:度伐利尤单抗联合抗CD73单克隆抗体Oleclumab治疗复发性卵巢癌的II期研究

NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2024-06-28

本II期开放标签非随机研究评估度伐利尤单抗联合抗CD73抗体Oleclumab治疗CD73阳性复发性上皮性卵巢癌的活性与安全性。25例患者接受静脉给药,16周疾病控制率为27%,中位无进展生存期2.7个月,中位总生存期8.4个月。联合治疗安全但抗肿瘤活性有限。

要点

  • CD73阳性复发性上皮性卵巢癌患者接受Oleclumab 3000 mg每2周联合度伐利尤单抗1500 mg每4周静脉给药。
  • 16周疾病控制率为27%,中位无进展生存期2.7个月(95%CI 2.2-4.2),中位总生存期8.4个月(95%CI 5.0-13.4)。
  • CD8阳性浸润与PD-L1表达在部分重叠的74%肿瘤样本中观察到,两者均与更好的疾病控制率无显著关联。

核心结论

  • Oleclumab联合度伐利尤单抗治疗复发性上皮性卵巢癌安全,但抗肿瘤活性有限。

研究设计与样本

  • II期开放标签非随机研究,纳入CD73阳性复发性上皮性卵巢癌患者,静脉给予Oleclumab 3000 mg每2周联合度伐利尤单抗1500 mg每4周。
  • 主要终点为16周疾病控制率,共纳入25例患者,中位年龄66岁(范围47-77岁),其中22例可评估治疗活性。
  • 对存档肿瘤组织行免疫组化评估PD-L1与CD8表达。

主要发现

  • 16周疾病控制率为27%,中位无进展生存期2.7个月(95%CI 2.2-4.2),中位总生存期8.4个月(95%CI 5.0-13.4)。
  • CD8阳性细胞浸润与肿瘤细胞PD-L1表达在部分重叠的74%肿瘤样本中观察到。
  • CD8阳性与PD-L1阳性均与更好的疾病控制率无显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In patients with epithelial ovarian cancer (EOC), the clinical efficacy of monotherapy with immune checkpoint inhibitors (ICIs) against PD-1/PD-L1 is modest. To enhance response rates to these immunotherapeutic agents and broaden the indications for their use, new approaches involving combinational therapy are needed. The immune regulator CD73 is a potential target, as it promotes tumor escape by producing immunosuppressive extracellular adenosine in the tumor microenvironment. Here, we present the results from the NSGO-OV-UMB1/ENGOT-OV-30 trial evaluating the activity of combining the anti-CD73 antibody oleclumab with the anti-PD-L1 checkpoint inhibitor durvalumab in patients with recurrent EOC. METHODS: In this phase II open-label non-randomized study, patients with CD73-positive relapsed EOC were intravenously administered oleclumab (3000 mg, Q2W) and durvalumab (1500 mg, Q4W). The primary endpoint was disease control rate (DCR) at 16 weeks. The expression of PD-L1 and CD8 was assessed by immunohistochemistry of archival tumors. RESULTS: This trial included 25 patients with a median age of 66 years (47-77 years). Twenty-two patients were evaluable for treatment activity analysis. The DCR was 27%, the median progression-free survival was 2.7 months (95% CI: 2.2-4.2) and the median overall survival was 8.4 months (95% CI: 5.0-13.4). Infiltration of CD8+ cells and PD-L1 expression on tumor cells were observed in partially overlapping sets of 74% of the tumor samples. Neither CD8- nor PD-L1-positivity were significantly associated with better DCR. CONCLUSIONS: Combined treatment with oleclumab and durvalumab was safe and demonstrated limited anti-tumor activity in patients with recurrent EOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Mirza MR, Tandaric L, Henriksen JR, et al. NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer. Gynecol Oncol. 2024. PMID: 38943691. doi:10.1016/j.ygyno.2024.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。